Nevertheless, some of the identified putative enhancers are predicted to regulate genes downstream of the oncogenic RAS pathway which is activated by secondary gain-of-function N- or K-RAS somatic mutations in 40–50% of MM cases3,19, thus highlighting the ability of our approach to also reveal chromatin traces of secondary driver genetic events. Here, KRAS is linked to Miyoshi myopathy.